Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Nkarta, Inc. (NKTX)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 48,660,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Nkarta is a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Co. has two product candidates, NKX101 and NKX019. Both product candidates were generated using Co.'s NK cell engineering platform. NKX101 is designed to improve the power of innate NK biology to detect and kill cancerous cells. NKX019 is based on the ability to treat a variety of B-cell malignancies by targeting the CD19 antigen that is found on these types of cancerous cells, where CD19-targeted engineered NK cells, T cells and monoclonal antibodies have demonstrated clinical activity.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 5,000,000 5,000,000 5,000,000 6,333,333
Total Buy Value $50,000,000 $50,000,000 $50,000,000 $69,999,995
Total People Bought 2 2 2 2
Total Buy Transactions 2 2 2 3
Total Shares Sold 12,510 37,385 42,746 138,518
Total Sell Value $154,387 $371,794 $393,775 $1,753,059
Total People Sold 2 5 6 6
Total Sell Transactions 2 7 14 32
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 127
  Page 1 of 6  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Shah Rajeev M. Director   –       •       •   2024-03-27 4 B $10.00 $30,000,000 I/I 3,000,000 10,050,818 2.25     -
   George Simeon   –       •      –    2024-03-27 4 B $10.00 $20,000,000 I/I 2,000,000 451,659 0.01     -
   Hastings Paul J Chief Executive Officer   •       •      –    2024-03-04 4 D $13.33 $1,834,768 D/D (137,642) 240,507     -
   Hastings Paul J Chief Executive Officer   •       •      –    2024-03-01 4 D $13.00 $160,654 D/D (12,358) 378,149     -
   Brandenberger Ralph Chief Technical Officer   •       –      –    2024-03-01 4 AS $12.51 $104,671 D/D (8,367) 79,972     -
   Brandenberger Ralph Chief Technical Officer   •       –      –    2024-03-01 4 OE $3.89 $26,308 D/D 6,763 88,339     -
   Trager James Chief Scientific Officer   •       –      –    2024-02-12 4 AS $12.00 $49,716 D/D (4,143) 149,415     -
   Shook David Chief Medical Officer   •       –      –    2024-01-16 4 S $8.74 $31,044 D/D (3,552) 114,980     -
   Brandenberger Ralph Chief Technical Officer   •       –      –    2024-01-16 4 S $8.74 $21,955 D/D (2,512) 81,576     -
   Trager James Chief Scientific Officer   •       –      –    2024-01-16 4 S $8.74 $39,854 D/D (4,560) 153,558     -
   Hager Alicia J. Chief Legal Officer   •       –      –    2024-01-16 4 S $8.74 $39,802 D/D (4,554) 107,942     -
   Hastings Paul J Chief Executive Officer   •       •      –    2024-01-16 4 S $8.74 $84,752 D/D (9,697) 390,507     -
   Trager James Chief Scientific Officer   •       –      –    2024-01-04 4 A $0.00 $0 D/D 56,000 158,118     -
   Shook David Chief Medical Officer   •       –      –    2024-01-04 4 A $0.00 $0 D/D 56,000 118,532     -
   Hastings Paul J Chief Executive Officer   •       •      –    2024-01-04 4 A $0.00 $0 D/D 85,000 400,204     -
   Hager Alicia J. Chief Legal Officer   •       –      –    2024-01-04 4 A $0.00 $0 D/D 56,000 112,496     -
   Levin Alyssa See Remarks   •       –      –    2024-01-04 4 A $0.00 $0 D/D 56,000 56,000     -
   Brandenberger Ralph Chief Technical Officer   •       –      –    2024-01-04 4 A $0.00 $0 D/D 56,000 84,088     -
   Shook David Chief Medical Officer   •       –      –    2023-08-21 4 S $1.83 $2,436 D/D (1,331) 60,532     -
   Hager Alicia J. Chief Legal Officer   •       –      –    2023-06-20 4 S $4.85 $3,400 D/D (701) 56,496     -
   Hastings Paul J Chief Executive Officer   •       •      –    2023-06-20 4 S $4.85 $8,264 D/D (1,704) 313,402     -
   Mahmood Nadir See Remarks   •       –      –    2023-06-20 4 S $4.85 $2,551 D/D (526) 85,776     -
   Trager James Chief Scientific Officer   •       –      –    2023-06-20 4 S $4.85 $2,129 D/D (439) 100,118     -
   Brandenberger Ralph Chief Technical Officer   •       –      –    2023-06-20 4 S $4.85 $1,072 D/D (221) 28,088     -
   Shook David Chief Medical Officer   •       –      –    2023-06-20 4 S $4.85 $2,129 D/D (439) 61,863     -
  127 Records found
  1  2  3  4  5  6   
  Page 1 of 6
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us